An official website of the United States government
Home
Name
FLAG-003
Alternate Names
None
Abbreviations
None
Category
Other therapy
Subcategory
None
NSC Number
None
Primary Site
Brain
Histology
Glioma
Remarks
February 3, 2023 FLAG-003, an investigational small molecule therapy developed by FLAG Therapeutics Inc. for the treatment of diffuse intrinsic pontine glioma—a rare, highly aggressive and difficult to treat brain tumor found in children—has been granted Rare Pediatric Disease designation from FDA.
March 4, 2016: FDA and the European Medicines Agency both granted Orphan Drug Designation to FLAG-003 for the treatment of glioma.
Orphan status is granted by the FDA to promote the development of products that demonstrate promise for treatment of rare diseases, those that affect fewer than 200,000 Americans annually.
CODE: code this drug in Other Treatment, assign code 2.
March 4, 2016: FDA and the European Medicines Agency both granted Orphan Drug Designation to FLAG-003 for the treatment of glioma.
Orphan status is granted by the FDA to promote the development of products that demonstrate promise for treatment of rare diseases, those that affect fewer than 200,000 Americans annually.
CODE: code this drug in Other Treatment, assign code 2.
Coding
Please see remarks for additional information
